Haemonetics (NYSE: HAE) reported Q3 EPS of $0.43, $0.03 better than the analyst estimate of $0.40. Revenue for the quarter came in at $227.8 million versus the consensus estimate of $220 million.

Sees FY17 revenues and EPS at high end of range.

For earnings history and earnings-related data on Haemonetics (HAE) click here.